42
Participants
Start Date
February 23, 2007
Primary Completion Date
April 22, 2015
Study Completion Date
April 22, 2015
BRB Lozenge
ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
Survey Administration
Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
Laboratory Biomarker Analysis
Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
pharmacological study
Correlative studies
Ohio State University Medical Center, Columbus
Ohio State University Comprehensive Cancer Center
OTHER